Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”-Reference-Cited by-同舟云学术

Alternative State-Level Financing for Hepatitis C Treatment—The “Netflix Model”

Published:2018-11-20 Issue:19 Volume:320 Page:1977
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Trusheim Mark R.¹,Cassidy William M.²³,Bach Peter B.⁴

Affiliation:

1. Sloan School of Management, Massachusetts Institute of Technology, Cambridge

2. US Senate

3. Louisiana State University Health Sciences Center, Baton Rouge

4. Health Outcomes Research Group, Memorial Sloan Kettering Cancer Center, New York, New York

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference9 articles.

1. Health care spending in the United States and other high-income countries.;Papanicolas;JAMA,2018

2. A novel strategy for increasing access to treatment for hepatitis C virus infection for Medicaid beneficiaries.;Sood;Ann Intern Med,2018

3. America’s overspend: how the pharmaceutical patent problem is fueling high drug prices. I-MAK. http://www.i-mak.org/wp-content/uploads/2017/10/Excess-Costs-Briefing-Paper-FINAL_-2017-10-24.pdf. Accessed May 25, 2018.

4. Louisiana Department of Health. Request for information on subscription payment models. http://www.ldh.la.gov/assets/docs/BehavioralHealth/Opioids/SubscriptionPaymentModelRFI.pdf. Accessed July 18, 2018.

5. KodjakA. Louisiana’s new approach to treating hepatitis C. National Public Radio. https://www.npr.org/2018/07/19/630378124/louisianas-new-approach-to-treating-hepatitis-c. Accessed July 26, 2018.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank;American Heart Journal;2024-04

2. Treating Hepatitis C Virus Infection in Jails as an Offset to Declines in Treatment Activity in the Community, New York City, NY, 2014–2020;AJPM Focus;2024-04

3. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer;Frontiers in Public Health;2024-02-15

4. Netflix and pill: is there a role for volume-delinked subscription-style payments beyond antimicrobials?’;Expert Review of Pharmacoeconomics & Outcomes Research;2023-10-17

5. Gene therapies, uncertainty, and decision-making: thinking about the last mile at the first step;Expert Review of Pharmacoeconomics & Outcomes Research;2023-08-09